should come as no surprise to DICP readers that Dr. Francke himself placed his mantle as editor and publisher on Harvey Whitney to carry on after his death, knowing full well that Whitney would continue the journal with the same pursuit of excellence that Francke required. One of his particular goals was to have his journal considered as "The New England Journal of Pharmacy" in concept and approach.
Dr Francke, Harvey Whitney and a few others learned last September while at the FIP meeting in France that I was contemplating leaving the editorship of a journal that I had served for some twelve years but none of us dreamed then that Dr. Francke would soon be passing on.
Shortly after Dr. Francke's death, Editor Whitney invited me to join with him and his associates as the Washington Editor and Correspondent of DICP with prime responsibility for a "Washington News and Comments" column, editorials, and a continuous search for valuable papers in the pharmacy practice, socioeconomic and government areas as I have been doing for over a decade. Needless to say, I was honored by the invitation and because of the invitation, this young septuagenarian pens this "Because" editorial. Starting next month my editorial will appear (on the last page of the journal as is my usual "hallmark" site) and within the journal (starting in June) will be found the Washington column.
As I start my eighth decade of life, I look forward to this editorial challenge and the opportunity to play a small role in the future of Dr. Francke's journal as its new editor, Harvey Whitney, continues to move towards Francke's appointed goal. Editors of professional journals need an alliance with readers and contributors. Therefore, I'll continue to meet with many of you at international, national, regional, state and local meetings. I look forward to a continuance of this association. My first meeting is scheduled for the APhA-ASHP meeting in Anaheim. I hope to greet many of you there. 
Future Direction of Drug Intelligence and Clinical Pharmacy

IN JANUARY 1967, DON FRANCKE FIRST PUBLISHED Dflig
Intelligence as an independent journal of hospital pharmacy, international in scope. He stated several objectives for the Journal in the first editorial, among which were 1) to make pharmacists more knowledgeable about drugs and thus enhance their ability to make intelligent judgments, 2) to encourage the development of specialization within the hospital pharmacy in such areas as drug information, clinical pharmacy, etc., and 3) to emphasize hospital pharmacists' modern, broad role as health care practitioners.
Francke quoted the Mirror to Hospital Pharmacy as follows :
". . . the dispensing function of the pharmacist, while important and even vital for patient care, is essentially a superficial practice of the profession which, by itself, does not utilize knowledge or skills sufficiently basic to merit professional recognition to the depth that lies within the grasp of hospital pharmacists." He then stated: ". .. The hospital pharmacist must be encouraged to relate more directly to the patient, the physician and the nurse, and to take his place on the health care team as a practitioner of clinical pharmacy in the same way that the physician is a practitioner of clinical medicine. This is a new role for the pharmacist, but it does not imply that his other roles be abandoned or neglected. . ."
In July 1969 the journal was renamed Drug Intelligence and Clinical Pharmacy, to establish and depict more clearly the interrelationships between these two subjects. This title is still appropriate for the journal today, since clinical pharmacists have increasingly become involved in the drug therapy decision-making process and apply therapeutic and pharmaceutical information to patient care.
I would like to describe briefly several new features planned for DICP.
Professor Dev Pathak of the University of Illinois College of Pharmacy will be editing a column entitled Research Methodology. An understanding of research methodology and statistics are needed to evaluate clinical research methodology and results appearing in the medical and pharmaceutical literature, and this understanding is critical for effective participation in research. Professor Pathak has extensive training in research methodology and the profession should benefit from his continuing efforts in this column.
Dr. Eric Jackson and Professor Alex Cardoni of the University of Connecticut Health Center and School of Pharmacy will edit a column entitled New Drug Evaluations. They will attempt to publish a critical analysis of all major new drugs that are marketed in the United States and Canada. They will coordinate their efforts with several leading drug information centers in both countries. This column will replace the single drug reviews appearing in the column entitled Drug Evaluation Data over the past several years.
Dr. Phil Hansten of Washington State University will publish a quarterly column entitled Drug Interaction Update. This column will be used to review new reported drug interactions critically, and to assess their clinical significance. This column will complement the drug interaction class reviews authored by Dr. Ed Hartshorn and appearing in DICP for many years.
I will be editing a column entitled Seminars in Clinical Pharmacy, in which a variety of therapeutic topics will be presented. Many Pharm.D. programs and clinical service departments present high level seminar series, and many of the topics discussed merit publication if properly written and referenced.
Other plans for DICP will be discussed in future editions of the journal. It is the intent of the editor, Drug Intelligence and Clinical Pharmacy VOL 13 APR 79
working with the Editorial Advisory Board and authors, to present therapeutic data and findings which are critical to those health care practitioners who directly influence the drug therapy decision-making process. Issues important to clinical practice and rational drug therapy will be aired in DICP. I feel that these directions for the journal are still part of the vast living stream of professional evolution encouraged and expounded by Dr. Donald Francke. Clinical practitioners and educators wishing to contribute to any of the established DICP columns should contact the column editor, preferably before beginning to write. Early guidance can thus be obtained and duplication of effort avoided. Whenever Pharm.D. students or residents make a contribution, appropriate coauthorship by experienced faculty should be included. Comments and suggestions are welcomed from all sources in the coming months.
DON C. MCLEOD, M . S C Chairman Editorial Advisory Board Drug Intelligence and Clinical Pharmacy Associate Professor and Chairman of the Division of Pharmacy Practice Ohio State University College of Pharmacy Columbus, OH 43210
Unit-of-Use Packaging Will Eliminate the Last Vestige of the Old Era
IN THE LAST DECADE, ORGANIZED PHABMACY m a d e t h e
transition in symbols from the mortar and pestle to the bowl of Hygeia. This symbolic change could be interpreted to mean that the pharmacist no longer relies on his ability to "mix and make" drugs but rather on his knowledge of drugs and drug therapy in serving his patients. Although the symbolic change is apparently complete, many practitioners in the profession still cling to the last vestige of the past: the packaging of drugs. In referring to the packaging of drugs, I include the tasks of counting and pouring, both of which should be relegated to the mortar and pestle era. It seems absurd for pharmacists to continue to perform these acts when modern technology permits the state-of-the-art to advance into a new era. As long as some pharmacists continue to spend a significant portion of their time involved in manual activities, they will never find time to develop a viable clinical practice.
The technological availability of unit-of-use packaging makes it possible for the pharmacist to completely disengage himself from packaging activities. As soon as these packages are made widely available by the pharmaceutical industry, then pharmacists will have sufficient time to fully utilize their clinical skills. The problem that prevents more rapid introduction of unit-of-use packages is not in the technical development but rather in the acceptance of the concept by physicians, pharmacists and patients. Until pharmacists exert some initiative and promote the concept, it will not be universally adopted. Like the early days of unit dose, pharmacists must also work with industry representatives and encourage them, for otherwise they will have little incentive.
Pharmacists in favor of unit-of-use packaging are getting support from the Food and Drug Administration. In January 1979, the FDA conducted a conference on this subject for the benefit of the industry and pharmacy practitioners. Specific objectives of the conference were:
1. Define unit-of-use packaging as it is and as it is becoming.
2. Become acquainted with the European experience in unit-of-use packaging.
3. Identify technical problems of the drug manufacturer, the pharmacist and the wholesaler.
4. Identify problems of acceptance by the health care providers.
5. Identify economic factors affecting the drug manufacturer, the pharmacist, the wholesaler and the consumer.
6. Determine desirability of defining drug coverage and unit-of-use package quantities.
Several speakers at this meeting were from European countries because "original pack" dispensing, as it is referred to abroad, has been accepted there for several years. Other speakers included representatives from medical practice, pharmacy practice, industry and the United States Pharmacopeial Convention. Within this issue of the journal is reproduced Dr. William M. Heller's presentation from the FDA meeting. Dr. Heller's proposal for a nongovernmental alternative to unit-of-use packaging merits serious consideration. 
Unit-of-Use Package
A definition: The unit-of-use dispensing package for the United States can be defined as a package carrying the manufacturer's recommended course of treatment (or, if for a chronic disease, a 30-day supply) and labeled with a tripart label: two parts of which are identical and one of which remains on the dispensed container and indicates the name of the drug, strength, manufacturer's lot number, the National Drug Code (NDC) number, expiration date, and the number of units in the container. A similar but self-adhesive label is attached to the prescription order of the prescriber for proof positive that an error has or has not been made. The third part is the well-known conventional label, found on all legend drug containers, that is removed by the dispenser at the time of dispensing and replaced by the pharmacy's usual label. (Ref.
Archambault, G. F.: An Evolution in Drug Dispensing, Hosp. Form. 14:70-79 (Jan.) 1979.) 
